SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/292433"
 

Search: onr:"swepub:oai:gup.ub.gu.se/292433" > Targeting CXCR1/2 D...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Maffi, P.IRCCS Osped San Raffaele, San Raffaele Diabet Res Inst, Milan, Italy (author)

Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-02-04
  • American Diabetes Association,2020

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/292433
  • https://gup.ub.gu.se/publication/292433URI
  • https://doi.org/10.2337/dc19-1480DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-409674URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:143241199URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • OBJECTIVE Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allotransplant recipients. RESEARCH DESIGN AND METHODS A phase 3, multicenter, randomized, double-blind, parallel-assignment study () was conducted in recipients of islet allotransplants randomized (2:1) to reparixin or placebo in addition to immunosuppression. Primary outcome was the area under the curve (AUC) for C-peptide during the mixed-meal tolerance test at day 75 +/- 5 after the first and day 365 +/- 14 after the last transplant. Secondary end points included insulin independence and standard measures of glycemic control. RESULTS The intention-to-treat analysis did not show a significant difference in C-peptide AUC at both day 75 (27 on reparixin vs. 18 on placebo, P = 0.99) and day 365 (24 on reparixin vs. 15 on placebo, P = 0.71). There was no statistically significant difference between treatment groups at any time point for any secondary variable. Analysis of patient subsets showed a trend for a higher percentage of subjects retaining insulin independence for 1 year after a single islet infusion in patients receiving reparixin as compared with patients receiving placebo (26.7% vs. 0%, P = 0.09) when antithymocyte globulin was used as induction immunosuppression. CONCLUSIONS In this first double-blind randomized trial, islet transplantation data obtained with reparixin do not support a role of CXCR1/2 inhibition in preventing islet inflammation-mediated damage.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Lundgren, T.Karolinska Institutet (author)
  • Tufveson, GunnarUppsala universitet,Transplantationskirurgi(Swepub:uu)gutuf839 (author)
  • Rafael, E.Skane Univ Hosp, Malmo, Sweden (author)
  • Shaw, J. A. M.Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England;Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Newcastle Upon Tyne, Tyne & Wear, England,IRCCS Osped San Raffaele, Milan, Italy (author)
  • Liew, A.Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England;Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Newcastle Upon Tyne, Tyne & Wear, England (author)
  • Saudek, F.Inst Clin & Expt Med, Prague, Czech Republic (author)
  • Witkowski, P.Univ Chicago Med, Transplantat Inst, Chicago, IL USA (author)
  • Golab, K.Univ Chicago Med, Transplantat Inst, Chicago, IL USA (author)
  • Bertuzzi, F.Osped Niguarda Ca Granda, Milan, Italy (author)
  • Gustafsson, Bengt,1946Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för fysiologi,Institute of Neuroscience and Physiology, Department of Physiology,Univ Gothenburg, Gothenburg, Sweden(Swepub:gu)xgbenk (author)
  • Daffonchio, L.Dompe Farmaceut SpA, Dept Res & Dev, Milan, Italy (author)
  • Ruffini, P. A.Dompe Farmaceut SpA, Dept Res & Dev, Milan, Italy (author)
  • Piemonti, L.IRCCS Osped San Raffaele, San Raffaele Diabet Res Inst, Milan, Italy (author)
  • Nano, R.IRCCS Osped San Raffaele, Milan, Italy (author)
  • Mercalli, A. (author)
  • Lampasona, V.IRCCS Osped San Raffaele, Milan, Italy (author)
  • Magistretti, P.IRCCS Osped San Raffaele, Milan, Italy (author)
  • Sordi, V.IRCCS Osped San Raffaele, Milan, Italy (author)
  • Antonio, S.IRCCS Osped San Raffaele, Milan, Italy (author)
  • Antonioli, B.Osped Niguarda Ca Granda, Milan, Italy (author)
  • Galuzzi, M.Osped Niguarda Ca Granda, Milan, Italy (author)
  • Tosca, M. C.Osped Niguarda Ca Granda, Milan, Italy (author)
  • De Carlis, L.Osped Niguarda Ca Granda, Milan, Italy (author)
  • Colussi, G.Osped Niguarda Ca Granda, Milan, Italy (author)
  • Korsgren, OlleUppsala universitet,Klinisk immunologi(Swepub:uu)ollekors (author)
  • Pollard, H.Skane Univ Hosp, Malmo, Sweden (author)
  • Karolinska InstitutetIRCCS Osped San Raffaele, San Raffaele Diabet Res Inst, Milan, Italy (creator_code:org_t)

Related titles

  • In:Diabetes Care: American Diabetes Association43:4, s. 710-7180149-59921935-5548

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view